# Microbiota-Gut-Kidney Axis and Targeted Therapeutic Strategies in Kidney Diseases

## TL;DR

This paper reviews how gut bacteria influence kidney health and explores new treatment strategies for kidney diseases.

## Contribution

The paper introduces the concept of the microbiota-gut-kidney axis and its potential as a novel therapeutic target for kidney diseases.

## Key findings

- Disruption of gut microbiota homeostasis worsens kidney function and creates a harmful cycle.
- Modulating gut microbiota may offer new therapeutic strategies for kidney diseases.
- Current therapeutic approaches show early promise but need further validation for long-term safety and effectiveness.

## Abstract

The gut microbiota, as a source of profound genetic and metabolic capacity, affects every aspect of human biology including health, development and aging, as well as disease. Studies have demonstrated the crosstalk between the gut microbiota and the kidney, which is directly referred to as the “microbiota-gut-kidney axis”. Most gut microbiota metabolites are associated with metabolic, immune, and inflammatory pathways. Disruption of gut microbiota homeostasis in patients with kidney disease contributes to further loss of kidney function, forming a vicious cycle. This discovery may provide a potential avenue of treatment for kidney diseases, creating a new therapeutic paradigm. Moreover, new therapeutic strategies seem to be beneficial for kidney health via the modulation of the gut microbiota. Although these strategies show early beneficial results, their long-term effectiveness and safety require further investigation and confirmation. In this review, we discuss the interactions between the gut microbiota and kidney diseases and explore related therapeutic strategies. A comprehensive understanding of the microbiota-gut-kidney axis will facilitate the development of efficient therapeutic measures for kidney diseases.